Juno Therapeutics
JT
Juno Therapeutics
Acquired
· 2013Biotechnology company focused on developing cancer immunotherapies.
Juno Therapeutics
Biotechnology company focused on developing cancer immunotherapies.
Last updated
About
Juno Therapeutics was a biopharmaceutical company founded in 2013, focused on developing a pipeline of cancer immunotherapy drugs, particularly CAR-T and TCR therapies. It was acquired by Celgene in 2018 for $9 billion.
Tags
Company Timeline
Funding rounds, employee growth, revenue, and exits over the same period. News mentions shown as markers.
No timeline data for this period
Score Breakdown
49Traction
40Team
70Visibility
0Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Juno Therapeutics do?
Juno Therapeutics was a biopharmaceutical company founded in 2013, focused on developing a pipeline of cancer immunotherapy drugs, particularly CAR-T and TCR therapies. It was acquired by Celgene in 2018 for $9 billion.
How much funding has Juno Therapeutics raised?
Juno Therapeutics has raised a total of $317M in funding. The most recent round on record is Series B.
Where is Juno Therapeutics headquartered?
Juno Therapeutics is headquartered in Seattle, United States.
When was Juno Therapeutics founded?
Juno Therapeutics was founded in 2013.
What industry does Juno Therapeutics operate in?
Juno Therapeutics operates in Biotechnology, Pharmaceuticals, Cancer Immunotherapy, CAR-T, TCR.
What is Juno Therapeutics's current status?
Juno Therapeutics's current operating status is: Acquired.